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COVID-19 and tuberculosis in South 
Africa: A dangerous combination
To the Editor: There has been much speculation during the past 
week about the catastrophe that awaits once coronavirus disease 2019 
(COVID-19) establishes itself in the poorest communities of South 
Africa (SA) and, importantly, in informal settlements. Evidence to date 
suggests that COVID-19 is efficiently passed from infected individuals 
via large droplets and hard-surface fomites. [1] Given the housing 
density and shared toilet and tap facilities in informal settlements, 
interventions such as frequent hand washing, social distancing and 
self-isolation will be particularly difficult to achieve. In addition, the 
disproportionate burden of HIV has left many making dire predictions 
for the consequences to the people and the health system if, or more 
appropriately when, COVID-19 reaches these communities.[2] In 
the wake of World TB Day, we would like to remind readers why 
tuberculosis (TB) is also an important and complex consideration for 
vulnerable populations in relation to COVID-19.
At the time of writing (24 March 2020), 554 cases of COVID-19 
have been detected and reported in SA, largely among people aged 
21 - 60 years.[3] No deaths have yet been reported, and the majority of 
cases are still imported by people who have recently travelled.[4] In the 
language of the day, the SA epidemic curve has just begun. Early data 
from China indicate that individuals most at risk for severe responses 
to COVID-19 are those aged >60 years and those with comorbidities 
such as chronic respiratory disease, hypertension, diabetes and 
cardiovascular disease.[5,6] To date, COVID-19 has not been studied 
in low- and middle-income countries with endemic HIV. With an 
estimated 7.7 million people living with HIV in SA,[7] concerns about 
the effect of COVID-19 on people with suppressed immune systems 
have largely dominated the conversation. Yet HIV is only one piece 
of the equation.
In SA, an estimated 301 000 people developed TB in 2019, nearly 
60% of whom were also HIV-infected.[8] It is unclear how COVID-19 
may manifest itself in this population. Regardless of HIV status, people 
with undiagnosed pulmonary TB (PTB), those with drug-resistant 
TB or complex presentations such as disseminated forms, and those 
who have only just begun PTB treatment may be at increased risk for 
severe responses if they become infected with COVID-19. As seen 
with PTB and silicosis, combined pulmonary diseases can multiply 
the gravity of the situation.[9,10] Moreover, common COVID-19 
symptoms (cough, fever, and to a lesser degree, shortness of breath) 
overlap with PTB, which may make distinguishing between the two 
problematic for healthcare workers in high-burden communities. 
Although sputum production, a common feature of PTB, is less 
common among individuals with COVID-19,[5] those with TB-HIV 
co-infection may not present with sputum production.[11] It will be 
important for clinicians to stay vigilant and consider PTB in their 
differential diagnosis of COVID-19 alongside the possibility of dual 
infection with COVID-19 and PTB, especially among people living 
with HIV. It is equally important that patients with confirmed or 
presumptive PTB symptoms be prioritised for COVID-19 testing.
TB and COVID-19 could result in poorer treatment outcomes, 
especially if TB treatment is interrupted.[12] Another danger is 
the inadvertent de-prioritisation of TB care if the health system 
becomes inundated with people experiencing severe acute respiratory 
syndrome from infection with SARS-CoV-2.[12,13] We run the risk of 
amplifying the effect when people with PTB return to communities 
without adequate treatment, with potential consequences well beyond 
the COVID-19 pandemic. It therefore behoves us as epidemiologists, 
clinicians and citizens to act now to stem the tide of COVID-19 
transmission through our practice and communication. The World 
Health Organization recommends that TB patients follow all 
recommended precautions against COVID-19 and continue taking 
TB treatment throughout the pandemic.[12] Ensuring continuity of 
TB care will require adequate stock of medication for patients to 
take home and the ramping up of digital technologies and other 
community support systems to provide outpatient and community 
care when it is safe to do so.[12] Given that self-isolation may be a 
challenge to those at heightened risk, appropriate testing and the 
strict enforcement of infection control protocols, cough etiquette, 
and segregation of people who may have either TB or SARS-CoV-2 
infection among in- and outpatients will be of paramount importance 
to limit further spread. TB-focused clinicians and health workers can 
also be vital points of reference for people infected with SARS-CoV-2 
and for health staff undertaking active case finding and contact 
tracing.[12]
The spread of COVID-19 among people living with HIV is a well-
founded concern in SA. The implications of TB with and without 
HIV must equally be considered. Factors related to PTB and TB-HIV 
co-infection may complicate clinical suspicion for either COVID-
19 or PTB, and require clinical vigilance. Given the unknowns 
regarding COVID-19 in the context of SA’s unique health burden, the 
resounding call to flatten the curve remains of critical importance.
Author contributions. JB researched and drafted the manuscript. TM and 
GS contributed to the concept of the manuscript and critically edited the 
content. SM, ZS, MP and AD critically edited the manuscript content.
J Boffa
McGill International TB Centre, McGill University, Montreal, Canada; 
and Centre for Rural Health, School of Nursing and Public Health, 
College of Health Sciences, University of KwaZulu-Natal, Durban, 
South Africa
jody.boffa@mail.mcgill.ca
T Mhlaba
Department of Public Health Medicine, School of Nursing and Public 
Health, College of Health Sciences, University of KwaZulu-Natal, 
Durban, South Africa
G Sulis
McGill International TB Centre, McGill University, Montreal, Canada
S Moyo
Social Aspects of Public Health Research Programme, Human  
Sciences Research Council, Cape Town, South Africa; and School of 
Public Health, Faculty of Health Sciences, University of Cape Town, 
South Africa
Z Sifumba
St Andrews Hospital, Harding, KwaZulu-Natal, South Africa
M Pai
McGill International TB Centre, McGill University, Montreal, Canada
A Daftary
Faculty of Health, York University, Toronto, Canada; and Centre 
for the AIDS Programme of Research in South Africa (CAPRISA), 
Durban, South Africa
This open-access article is distributed under 
Creative Commons licence CC-BY-NC 4.0.
342       May 2020, Vol. 110, No. 5
CORRESPONDENCE
1. Preiser W, van Zyl G, Dramowski A. COVID-19: Getting ahead of the epidemic curve by early 
implementation of social distancing. S Afr Med J 2020;110(4):258. https://doi.org/10.7196/SAMJ.2020.
v110i4.14720 
2. Shisana O, Rehle T, Simbayi LC, et al. South African National HIV Prevalence, Incidence and Behaviour 
Survey, 2012. Cape Town: HSRC Press, 2014. http://ecommons.hsrc.ac.za/handle/20.500.11910/2490 
(accessed 25 March 2020).
3. National Department of Health, South Africa. Minister of Health Update [Twitter] 2020. https://twitter.
com/HealthZA/status/1242507959852302336?s=19 (accessed 24 March 2020).
4. National Department of Health, South Africa. Latest confirmed cases of COVID-19 (23rd March 
2020). https://sacoronavirus.co.za/2020/03/23/latest-confirmed-cases-of-covid-19-23rd-march-2020/ 
(accessed 24 March 2020).
5. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, 
China. Lancet 2020 (epub 24 January 2020). https://doi.org/10.1016/S0140-6736(20)30183-5
6. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 
in Wuhan, China: A retrospective cohort study. Lancet 2020 (epub 11 March 2020). https://doi.
org/10.1016/S0140-6736(20)30566-3
7. World Health Organization. Global Health Observatory data repository: Antiretroviral coverage estimates 
by country: 2018. 2019. https://apps.who.int/gho/data/node.main.626 (accessed 25 March 2020).
8. World Health Organization. Country profiles: South Africa. In: Global Tuberculosis Report 2019. 
Geneva: WHO, 2019. https://www.who.int/tb/publications/global_report/en/ (accessed 24 March 2020).
9. Snider Jr DE. The relationship between tuberculosis and silicosis. Am Rev Respir Dis 1978;118:455-460.
10. Cowie RL. The epidemiology of tuberculosis in gold miners with silicosis. Am J Respir Crit Care Med 
1994;150(5):1460-1462.
11. Lawn SD, Bekker SG. Co-pathogenesis of tuberculosis and HIV. In: Schaaf HS, Zumla AI, eds. 
Tuberculosis: A Comprehensive Clinical Reference. London: Elsevier, 2009:96-106.
12. World Health Organization. WHO Information Note: Tuberculosis and COVID-19. 20 March 2020. 
https://www.who.int/tb/COVID_19considerations_tuberculosis_services.pdf (accessed 24 March 2020).
13. Pai M. COVID-19 coronavirus and tuberculosis: We need a damage control plan. Forbes, 17 March 2020. 
https://www.forbes.com/sites/madhukarpai/2020/03/17/covid-19-and-tuberculosis-we-need-a-damage-
control-plan/#70ea2496295c (accessed 24 March 2020).
S Afr Med J 2020;110(5):341-342. https://doi.org/10.7196/SAMJ.2020.v110i5.14747
